Wells Fargo & Company Tempest Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 98 shares of TPST stock, worth $171. This represents 0.0% of its overall portfolio holdings.
Number of Shares
98
Previous 96
2.08%
Holding current value
$171
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding TPST
# of Institutions
32Shares Held
1.39MCall Options Held
161KPut Options Held
78K-
Black Rock Inc. New York, NY508KShares$889,3410.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA176KShares$308,3370.0% of portfolio
-
Geode Capital Management, LLC Boston, MA132KShares$231,1450.0% of portfolio
-
Fil LTD Hamilton, D0130KShares$226,7630.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX106KShares$184,8000.05% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $18.2M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...